Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Compass Therapeutics, Inc.

Market Cap 369M 318M 293M 276M 518M 34.84B 522M 3.47B 1.35B 17.1B 1.39B 1.36B 59.15B P/E 2026 *
-4.68x
P/E 2027 * -4.41x
Enterprise Value 219M 189M 174M 164M 307M 20.68B 310M 2.06B 802M 10.15B 823M 805M 35.12B EV / Sales 2026 *
-98.9x
EV / Sales 2027 * 9.24x
Free-Float
87.55%
Yield 2026 *
-
Yield 2027 * -
1 day+4.06%
1 week+6.77%
Current month-13.87%
1 month+10.22%
3 months-62.39%
6 months-58.67%
Current year-61.82%
1 week 1.96
Extreme 1.96
2.14
1 month 1.75
Extreme 1.7506
2.47
Current year 1.61
Extreme 1.61
6.88
1 year 1.61
Extreme 1.61
6.88
3 years 0.76
Extreme 0.765
6.88
5 years 0.76
Extreme 0.765
6.88
10 years 0.76
Extreme 0.765
11
Manager TitleAgeSince
Chief Executive Officer 65 27/05/2024
Director of Finance/CFO 54 08/12/2024
Chief Tech/Sci/R&D Officer 56 31/12/2025
Director TitleAgeSince
Director/Board Member 65 31/12/2013
Director/Board Member 64 31/12/2014
Chairman 61 31/12/2014
Date Insider Type Main position Quantity % Market Cap.
04-28Buy

Controller/Auditor

15,000 0.0083%
04-28Buy

General Counsel

25,000 0.0139%
02-07Tax

Chief Executive Officer

36,687 0.0206%
Change 5-day change 1-year change 3-year change Capi.($)
+4.06%+6.77%-6.39%-33.66% 355M
+3.23%+2.25%+65.02%+113.87% 54.54B
+0.04%+1.20%+47.67%+36.75% 43.86B
+3.04%+7.05%-12.15%-18.06% 22.63B
+3.07%+7.15%-1.82%+392.25% 20.7B
+3.42%+3.27%+24.43%-33.79% 15.84B
+5.27%+1.87%+13.67%-38.81% 14.83B
+0.65%-0.27%+26.80%+174.70% 13.1B
+3.42%+5.63%+21.60% - 12.66B
+1.92%+2.43%+112.68%+232.59% 11.68B
Average +2.81%+1.49%+29.15%+91.76% 21.02B
Weighted average by Cap. +2.47%+2.14%+37.35%+98.29%

Financials

2026 *2027 *
Net sales -2.22M -1.91M -1.76M -1.65M -3.11M -209M -3.13M -20.82M -8.11M -103M -8.31M -8.14M -355M 25.67M 22.15M 20.36M 19.17M 36.02M 2.42B 36.32M 241M 93.95M 1.19B 96.36M 94.3M 4.11B
Net income -82.94M -71.55M -65.78M -61.92M -116M -7.83B -117M -780M -304M -3.84B -311M -305M -13.29B -89.85M -77.51M -71.26M -67.08M -126M -8.48B -127M -845M -329M -4.16B -337M -330M -14.4B
Net Debt -150M -129M -119M -112M -210M -14.16B -212M -1.41B -549M -6.95B -563M -551M -24.03B -132M -114M -105M -98.54M -185M -12.46B -187M -1.24B -483M -6.11B -495M -485M -21.15B
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
39
Date Price Change Volume
17/06/26 2.050 $ +4.06% 3,743,227
16/06/26 1.970 $ -3.43% 2,532,656
15/06/26 2.040 $ +0.49% 2,174,768
12/06/26 2.030 $ +1.00% 2,049,688
11/06/26 2.010 $ +4.69% 3,589,309
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
2.050USD
Average target price
8.818USD
Spread / Average Target
+330.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CMPX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!